HCM FY 2022 Earnings — HUTCHMED (China) Limited Revenue & Financial Results | Market Cap Arena

HCMHUTCHMED (China) Limited

$3B

FY 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$426M+19.7% YoY

Gross Profit

$115M27.0% margin

Operating Income

-$410M-96.1% margin

Net Income

-$361M-84.6% margin

EPS (Diluted)

$-2.15

Cash Flow

Operating Cash Flow

-$269M

Free Cash Flow

-$305M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$393M

Stockholders' Equity

$610M

Cash & Equivalents

$313M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$426M	$356M	+19.7%
Gross Profit	$115M	$98M	+17.8%
Operating Income	-$410M	-$344M	-19.0%
Net Income	-$361M	-$195M	-85.4%